Somai Pharmaceuticals has entered the Swiss market through a strategic partnership with Dascoli Pharma AG.
Michael Sassano, CEO of SOMAÍ Pharmaceuticals, emphasized the significance of the company's latest expansion, stating: "With our continued entry into new global markets like Switzerland, SOMAÍ is further solidifying its role as a leader in the cannabis pharmaceutical sector. By maintaining our focus on quality, innovation, and accessibility, we are helping shape the future of cannabinoid-based medicine."
Andrew Petronanos, Founder & CEO of Dascoli Pharma AG, also highlighted the strength of this partnership, saying: "With SOMAÍ's scientifically advanced extract portfolio and our expertise in Swiss pharmaceutical distribution and education, this collaboration will help improve patient access, enhance industry standards, and contribute to the ongoing evolution of medical cannabis in Switzerland."
Switzerland is the latest addition to SOMAÍ's expanding global footprint, reinforcing its position as a leader in cannabinoid-based pharmaceuticals. The company is already commercially active in the United Kingdom, Germany, and Australia, with Ireland and Poland set to launch in 2025.
For more information:
Somai Pharmaceuticals
www.somaipharma.eu